ZA200109906B - Method for treating chronic pain using MEK inhibitors. - Google Patents
Method for treating chronic pain using MEK inhibitors.Info
- Publication number
- ZA200109906B ZA200109906B ZA200109906A ZA200109906A ZA200109906B ZA 200109906 B ZA200109906 B ZA 200109906B ZA 200109906 A ZA200109906 A ZA 200109906A ZA 200109906 A ZA200109906 A ZA 200109906A ZA 200109906 B ZA200109906 B ZA 200109906B
- Authority
- ZA
- South Africa
- Prior art keywords
- chronic pain
- treating chronic
- mek inhibitors
- mek
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14441899P | 1999-07-16 | 1999-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200109906B true ZA200109906B (en) | 2003-05-28 |
Family
ID=22508500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200109906A ZA200109906B (en) | 1999-07-16 | 2001-11-30 | Method for treating chronic pain using MEK inhibitors. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1202731A2 (de) |
JP (1) | JP2003504398A (de) |
KR (1) | KR20020015376A (de) |
CN (1) | CN1358094A (de) |
AU (1) | AU6068600A (de) |
CA (1) | CA2377092A1 (de) |
CO (1) | CO5190704A1 (de) |
HU (1) | HUP0202319A3 (de) |
IL (1) | IL147150A0 (de) |
PE (1) | PE20010546A1 (de) |
PL (1) | PL352835A1 (de) |
WO (1) | WO2001005390A2 (de) |
ZA (1) | ZA200109906B (de) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR035971A1 (es) | 2001-05-16 | 2004-07-28 | Cephalon Inc | Metodos para el tratamiento y la prevencion del dolor |
AU2002310441A1 (en) * | 2001-06-14 | 2003-01-02 | The Regents Of The University Of California | A novel signaling pathway for the production of inflammatory pain and neuropathy |
EP2275102B1 (de) | 2002-03-13 | 2015-07-29 | Array Biopharma, Inc. | N3-alkylierte Benzimidazolderivate als MEK-Inhibitoren |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US20030216460A1 (en) * | 2002-03-13 | 2003-11-20 | Wallace Eli M. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
GB0213383D0 (en) * | 2002-06-11 | 2002-07-24 | Cambridge Biotechnology Ltd | Therapeutic conditions |
US20050004186A1 (en) * | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
CA2532067C (en) * | 2003-07-24 | 2010-12-21 | Stephen Douglas Barrett | N-methyle-substituted benzamidazoles |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7781595B2 (en) * | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
AU2004293018B2 (en) | 2003-11-19 | 2010-02-18 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
RU2006121990A (ru) | 2003-11-21 | 2007-12-27 | Эррэй Биофарма Инк. (Us) | Ингибиторы протеинкиназ акт |
PT2361905E (pt) | 2005-05-18 | 2013-03-18 | Array Biopharma Inc | Inibidores heterocíclicos de mek e seus métodos de utilização |
CA2612419C (en) | 2005-06-23 | 2017-06-13 | Array Biopharma Inc. | Process for preparing benzimidazole compounds |
EP1934174B1 (de) | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
CA2656566C (en) | 2006-07-06 | 2014-06-17 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
PT2049500E (pt) | 2006-07-06 | 2011-12-23 | Array Biopharma Inc | Ciclopenta[d]pirimidinas como inibidores da proteína quinase akt |
JP5231411B2 (ja) | 2006-07-06 | 2013-07-10 | アレイ バイオファーマ、インコーポレイテッド | Aktプロテインキナーゼ阻害剤としてのジヒドロチエノピリミジン |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
CA2671982C (en) | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
CN101918373B (zh) | 2007-07-05 | 2013-06-05 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
KR20150089099A (ko) | 2007-07-05 | 2015-08-04 | 어레이 바이오파마 인크. | Akt 단백질 키나제 억제제로서의 피리미딜 시클로펜탄 |
PE20131210A1 (es) | 2007-12-19 | 2013-10-31 | Genentech Inc | Derivados de 5-anilinoimidazopiridina como inhibidores de mek |
JP5710268B2 (ja) | 2007-12-19 | 2015-04-30 | ジェネンテック, インコーポレイテッド | 8−アニリノイミダゾピリジン及びその抗ガン及び/又は抗炎症剤としての使用 |
BRPI0819505A2 (pt) | 2007-12-21 | 2017-04-04 | Genentech Inc | "composto, composição farmacêutica, método para inibir o crescimento celular anormal e método para tratar uma doença inflamatória" |
EP2247578B1 (de) | 2008-01-09 | 2013-05-22 | Array Biopharma, Inc. | Hydroxylierte pyrimidylcyclopentane als akt-proteinkinaseinhibitoren |
ES2401685T3 (es) | 2008-01-09 | 2013-04-23 | Array Biopharma, Inc. | Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT |
RU2495028C2 (ru) | 2008-07-01 | 2013-10-10 | Дженентек, Инк. | Изоиндолоны и способы их применения |
US8993630B2 (en) | 2008-11-10 | 2015-03-31 | Bayer Intellectual Property Gmbh | Substituted sulphonamido phenoxybenzamides |
CA2777071A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
JP2013508318A (ja) | 2009-10-21 | 2013-03-07 | バイエル・ファルマ・アクチェンゲゼルシャフト | 置換されたベンゾスルホンアミド誘導体 |
EP2491016A1 (de) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituierte benzosulfonamide |
US9045429B2 (en) | 2010-10-29 | 2015-06-02 | Bayer Intellectual Property Gmbh | Substituted phenoxypyridines |
JP6147246B2 (ja) | 2011-04-01 | 2017-06-14 | ジェネンテック, インコーポレイテッド | Akt及びmek阻害剤化合物の組み合わせ、及び使用方法 |
EP2694072B1 (de) | 2011-04-01 | 2017-11-29 | Genentech, Inc. | Kombination von akt-hemmer-verbindung und abirateron zur verwendung in therapeutischen verfahren |
ES2396764B1 (es) | 2011-11-02 | 2013-12-19 | Universidad Autónoma de Madrid | FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES. |
WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
JP2015533782A (ja) | 2012-08-28 | 2015-11-26 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 |
GEP201706690B (en) | 2012-10-12 | 2017-06-26 | Exelixis Inc | Novel process for making compounds for use in treatment of cancer |
HRP20240033T1 (hr) * | 2012-10-19 | 2024-03-29 | Array Biopharma, Inc. | Formulacija koja sadrži inhibitor mek |
HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
PL3024819T3 (pl) | 2013-07-25 | 2018-08-31 | Janssen Sciences Ireland Uc | Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
ES2655518T3 (es) | 2013-10-23 | 2018-02-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B |
CN104774188B (zh) * | 2014-01-15 | 2019-10-11 | 江苏恒瑞医药股份有限公司 | 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用 |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
ES2792848T3 (es) | 2014-02-05 | 2020-11-12 | Novira Therapeutics Inc | Politerapia para el tratamiento de infecciones por VHB |
EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
CN107847762A (zh) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
AR106192A1 (es) | 2015-09-29 | 2017-12-20 | Novira Therapeutics Inc | Formas cristalinas de un agente antiviral contra la hepatitis b |
EP3848026A1 (de) | 2016-04-15 | 2021-07-14 | Novira Therapeutics Inc. | Kombinationen und verfahren mit einem kapsid-anordnungsinhibitor |
AR108257A1 (es) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
EA202092171A1 (ru) | 2018-03-14 | 2020-12-01 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Схема дозирования модулятора сборки капсида |
CN113454077A (zh) | 2019-02-22 | 2021-09-28 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
KR20220005549A (ko) | 2019-05-06 | 2022-01-13 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유도성 질환의 치료에 유용한 아미드 유도체 |
CN110981819B (zh) * | 2019-12-24 | 2022-07-01 | 广西师范大学 | 一种喹喔啉类信号通路抑制剂及其制备方法和应用 |
CN114788867A (zh) * | 2022-04-24 | 2022-07-26 | 天津医科大学总医院 | Map2k1作为化疗后神经痛的治疗靶点的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
SK9832001A3 (en) * | 1999-01-13 | 2003-02-04 | Warner Lambert Co | Benzoheterocycles and their use as MEK inhibitors |
-
2000
- 2000-07-05 CN CN00809478A patent/CN1358094A/zh active Pending
- 2000-07-05 CA CA002377092A patent/CA2377092A1/en not_active Abandoned
- 2000-07-05 IL IL14715000A patent/IL147150A0/xx unknown
- 2000-07-05 KR KR1020027000589A patent/KR20020015376A/ko not_active Application Discontinuation
- 2000-07-05 AU AU60686/00A patent/AU6068600A/en not_active Abandoned
- 2000-07-05 PL PL00352835A patent/PL352835A1/xx unknown
- 2000-07-05 WO PCT/US2000/018345 patent/WO2001005390A2/en not_active Application Discontinuation
- 2000-07-05 HU HU0202319A patent/HUP0202319A3/hu unknown
- 2000-07-05 JP JP2001510447A patent/JP2003504398A/ja active Pending
- 2000-07-05 EP EP00947013A patent/EP1202731A2/de not_active Withdrawn
- 2000-07-14 CO CO00053306A patent/CO5190704A1/es not_active Application Discontinuation
- 2000-07-14 PE PE2000000704A patent/PE20010546A1/es not_active Application Discontinuation
-
2001
- 2001-11-30 ZA ZA200109906A patent/ZA200109906B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001005390A3 (en) | 2001-05-17 |
AU6068600A (en) | 2001-02-05 |
CN1358094A (zh) | 2002-07-10 |
PE20010546A1 (es) | 2001-06-04 |
IL147150A0 (en) | 2002-08-14 |
KR20020015376A (ko) | 2002-02-27 |
WO2001005390A2 (en) | 2001-01-25 |
HUP0202319A3 (en) | 2004-12-28 |
CA2377092A1 (en) | 2001-01-25 |
CO5190704A1 (es) | 2002-08-29 |
EP1202731A2 (de) | 2002-05-08 |
HUP0202319A2 (en) | 2002-10-28 |
PL352835A1 (en) | 2003-09-08 |
JP2003504398A (ja) | 2003-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200109906B (en) | Method for treating chronic pain using MEK inhibitors. | |
ZA200109903B (en) | Method for treating chronic pain using MEK inhibitors. | |
HUP0202180A2 (en) | Method for treating chronic pain using mek inhibitors | |
IL147619A0 (en) | Method for treating chronic pain using mek inhibitors | |
EG23200A (en) | Method for treating multiple wellbore intervals. | |
AP2210A (en) | 4-tetrazolyl-4phenylpiperidine derivatives for treating pain. | |
EP1215963A4 (de) | Verfahren zur behandlung neuropathischer schmerzen unter verwendung von heteroarylmethansulfonamiden | |
HK1010220A1 (en) | Method for surface treatment. | |
AU2001238369A1 (en) | Method for treating thyroid disorders | |
AU1484202A (en) | Method for treating films | |
HK1035243A1 (en) | Method and apparatus for executing prefetch instructions. | |
PL340206A1 (en) | Effluent water treatment, method and apparatus | |
EP1446087A4 (de) | Verfahren zur behandlung von nichtneuropathischen schmerzen | |
AU7331300A (en) | Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome | |
AU2002241736A1 (en) | Method for preventing or treating pain by administering an endothelin antagonist | |
HK1043603A1 (en) | Hard surface treating agent, stain-proofing agent and method for surface treatment. | |
MXPA03003632A (es) | Metodo para tratamiento de tumores usando terapia de combinacion. | |
ZA200309733B (en) | Method and apparatus for distributing treatment agents. | |
ZA200202841B (en) | Apparatus for treating fluids. | |
HK1033551A1 (en) | Method for treating copd. | |
GB0123898D0 (en) | Method for treating objects | |
GB0118883D0 (en) | Method for treating objects | |
GB0123897D0 (en) | Method for treating objects | |
GB0122810D0 (en) | Method for treating objects | |
ZA200007396B (en) | Method of treatment. |